142 related articles for article (PubMed ID: 26974599)
1. Investigation of the Binding Interaction of Fatty Acids with Human G Protein-Coupled Receptor 40 Using a Site-Specific Fluorescence Probe by Flow Cytometry.
Ren XM; Cao LY; Zhang J; Qin WP; Yang Y; Wan B; Guo LH
Biochemistry; 2016 Apr; 55(13):1989-96. PubMed ID: 26974599
[TBL] [Abstract][Full Text] [Related]
2. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
[TBL] [Abstract][Full Text] [Related]
3. Free fatty acid receptors: structural models and elucidation of ligand binding interactions.
Tikhonova IG; Poerio E
BMC Struct Biol; 2015 Sep; 15():16. PubMed ID: 26346819
[TBL] [Abstract][Full Text] [Related]
4. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry-based binding assay for GPR40 (FFAR1; free fatty acid receptor 1).
Hara T; Hirasawa A; Sun Q; Koshimizu TA; Itsubo C; Sadakane K; Awaji T; Tsujimoto G
Mol Pharmacol; 2009 Jan; 75(1):85-91. PubMed ID: 18927207
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120).
Hudson BD; Shimpukade B; Milligan G; Ulven T
J Biol Chem; 2014 Jul; 289(29):20345-58. PubMed ID: 24860101
[TBL] [Abstract][Full Text] [Related]
7. Physiology and therapeutics of the free fatty acid receptor GPR40.
Huang H; Dai MH; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235
[TBL] [Abstract][Full Text] [Related]
8. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84.
Wang J; Wu X; Simonavicius N; Tian H; Ling L
J Biol Chem; 2006 Nov; 281(45):34457-64. PubMed ID: 16966319
[TBL] [Abstract][Full Text] [Related]
9. Antagonizing potencies of saturated and unsaturated long-chain free fatty acids to isoflurane in goldfish.
Hanada R; Tatara T; Iwao Y
J Anesth; 2004; 18(2):89-93. PubMed ID: 15127255
[TBL] [Abstract][Full Text] [Related]
10. Identification of residues important for agonist recognition and activation in GPR40.
Sum CS; Tikhonova IG; Neumann S; Engel S; Raaka BM; Costanzi S; Gershengorn MC
J Biol Chem; 2007 Oct; 282(40):29248-55. PubMed ID: 17699519
[TBL] [Abstract][Full Text] [Related]
11. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors.
Tuo Y; Feng DD; Wang DF; Sun J; Li SB; Chen C
Clin Exp Pharmacol Physiol; 2012 May; 39(5):423-8. PubMed ID: 22332921
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Characterization of a Promising Novel FFAR1/GPR40 Targeting Fluorescent Probe for β-Cell Imaging.
Bertrand R; Wolf A; Ivashchenko Y; Löhn M; Schäfer M; Brönstrup M; Gotthardt M; Derdau V; Plettenburg O
ACS Chem Biol; 2016 Jun; 11(6):1745-54. PubMed ID: 27115176
[TBL] [Abstract][Full Text] [Related]
13.
Vink G; Nebel JC; Wren SP
Future Med Chem; 2021 Apr; 13(8):691-700. PubMed ID: 33715419
[No Abstract] [Full Text] [Related]
14. Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics.
Yonezawa T; Kurata R; Yoshida K; Murayama MA; Cui X; Hasegawa A
Curr Med Chem; 2013; 20(31):3855-71. PubMed ID: 23862620
[TBL] [Abstract][Full Text] [Related]
15. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.
Lu J; Byrne N; Wang J; Bricogne G; Brown FK; Chobanian HR; Colletti SL; Di Salvo J; Thomas-Fowlkes B; Guo Y; Hall DL; Hadix J; Hastings NB; Hermes JD; Ho T; Howard AD; Josien H; Kornienko M; Lumb KJ; Miller MW; Patel SB; Pio B; Plummer CW; Sherborne BS; Sheth P; Souza S; Tummala S; Vonrhein C; Webb M; Allen SJ; Johnston JM; Weinglass AB; Sharma S; Soisson SM
Nat Struct Mol Biol; 2017 Jul; 24(7):570-577. PubMed ID: 28581512
[TBL] [Abstract][Full Text] [Related]
17. Generating thermostabilized agonist-bound GPR40/FFAR1 using virus-like particles and a label-free binding assay.
Hirozane Y; Motoyaji T; Maru T; Okada K; Tarui N
Mol Membr Biol; 2014 Aug; 31(5):168-75. PubMed ID: 25068810
[TBL] [Abstract][Full Text] [Related]
18. Molecular simulations of β-lactoglobulin complexed with fatty acids reveal the structural basis of ligand affinity to internal and possible external binding sites.
Evoli S; Guzzi R; Rizzuti B
Proteins; 2014 Oct; 82(10):2609-19. PubMed ID: 24916607
[TBL] [Abstract][Full Text] [Related]
19. Efficient odd straight medium chain free fatty acid production by metabolically engineered Escherichia coli.
Wu H; San KY
Biotechnol Bioeng; 2014 Nov; 111(11):2209-19. PubMed ID: 24889416
[TBL] [Abstract][Full Text] [Related]
20. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
